Travere Therapeutics slides after forecasting Q4 sales below estimates

Shares of drug developer Travere Therapeutics TVTX.O fall 25.9% to $25.58

Company said late on Monday it expects total U.S. sales for Q4 to be about $127 million, below Wall Street estimates of $142.2 million - data compiled by LSEG

For 2025, co expects total U.S. sales to be about $410 million vs estimates of $502.96 million

Co to restart late-stage study of experimental therapy, pegtibatinase, in patients with rare metabolic disorder in Q1 2026

TVTX said it responded to FDA requests for more data on Filspari’s benefit in focal segmental glomerulosclerosis patients, and the agency is reviewing those submissions

As of last close, stock had risen 83.4% in the past 12 months